Skip to main content
SpringerLink
Log in

Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The aims of this study were to investigate the utility of [18F]F-Florastamin, a novel prostate-specific membrane antigen (PSMA)-targeted PET radiotracer with facile radiochemistry, relative to the conventional imaging for the detection of sties of disease and evaluate the effect of multi-timepoint imaging with [18F]F-Florastamin PET on lesion detectability.

Methods

Eight prostate cancer patients with known or suspected recurrence who underwent [18F]F-Florastamin PET/CT at 1-h and 2-h imaging time-points were included in this prospective pilot study. [18F]F-Florastamin PET images were interpreted visually and quantitatively at both time points and compared with CIM.

Results

[18F]F-Florastamin PET was superior to CT in the detection of active osseous metastases and small-sized metastatic lymph nodes that do not fall under the anatomic imaging size criteria for metastasis. Multi-timepoint imaging showed a significant reduction in the blood pool, bone marrow and muscular uptake, and increase in liver uptake over time. There is a significant improvement in tumor-to-background ratio (TBR) at the 2-h imaging time-point (P = 0.04). The mean percentage change in TBR at 2-h was 21% (SD = 0.31).

Conclusions

[18F]F-Florastamin is a promising new radioligand for PSMA-targeted PET with suitable lesion detectability and high TBR at both time points.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rowe SP, Gorin MA, Pomper MG. Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications. Annu Rev Med. 2019;70:461–77. https://doi.org/10.1146/annurev-med-062117-073027.

    Article  CAS  PubMed  Google Scholar 

  2. Rowe SP, Buck A, Bundschuh RA, Lapa C, Serfling SE, Derlin T, et al. [18F]DCFPyL PET/CT for imaging of prostate cancer. Nuklearmedizin. 2022;61:240–6. https://doi.org/10.1055/a-1659-0010.

    Article  PubMed  Google Scholar 

  3. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6. https://doi.org/10.1007/s00259-012-2069-0.

    Article  CAS  PubMed  Google Scholar 

  4. Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62. https://doi.org/10.1016/j.apradiso.2012.06.034.

    Article  CAS  PubMed  Google Scholar 

  5. Gorin MA, Pomper MG, Rowe SP. PSMA-targeted imaging of prostate cancer: the best is yet to come. BJU Int. 2016;117:715–6. https://doi.org/10.1111/bju.13435.

    Article  PubMed  Google Scholar 

  6. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84. https://doi.org/10.1007/s11307-015-0866-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527–32. https://doi.org/10.2967/jnumed.119.234187.

    Article  CAS  PubMed  Google Scholar 

  8. Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. (18)F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10:1–16. https://doi.org/10.7150/thno.37894.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Giesel FL, Cardinale J, Schafer M, Neels O, Benesova M, Mier W, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–30. https://doi.org/10.1007/s00259-016-3447-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, et al. Intraindividual comparison of (18)F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61:729–34. https://doi.org/10.2967/jnumed.119.234898.

    Article  CAS  PubMed  Google Scholar 

  11. Lee I, Lim I, Byun BH, Kim BI, Choi CW, Woo SK, et al. A microdose clinical trial to evaluate [(18)F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:95–102. https://doi.org/10.1007/s00259-020-04883-y.

    Article  CAS  PubMed  Google Scholar 

  12. Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, et al. Semiquantitative parameters in PSMA-targeted PET imaging with [(18)F]DCFPyL: intrapatient and interpatient variability of normal organ uptake. Mol Imaging Biol. 2020;22:181–9. https://doi.org/10.1007/s11307-019-01376-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [(68)Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12102788.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411–9. https://doi.org/10.1007/s11307-016-0957-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Alberts I, Prenosil G, Mingels C, Bohn KP, Viscione M, Sari H, et al. Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences. Eur J Nucl Med Mol Imaging. 2021;48:4456–62. https://doi.org/10.1007/s00259-021-05438-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hohberg M, Kobe C, Tager P, Hammes J, Schmidt M, Dietlein F, et al. Combined early and late [(68)Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558–66. https://doi.org/10.1007/s11307-018-1263-2.

    Article  CAS  PubMed  Google Scholar 

  17. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74. https://doi.org/10.1007/s11307-015-0850-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S, et al. The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47:642–51. https://doi.org/10.1007/s00259-019-04552-9.

    Article  CAS  PubMed  Google Scholar 

  19. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88. https://doi.org/10.1007/s00259-016-3573-4.

    Article  CAS  PubMed  Google Scholar 

  20. Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET/CT imaging with (68)Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58:750–5. https://doi.org/10.2967/jnumed.116.183483.

    Article  CAS  PubMed  Google Scholar 

  21. Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. (68)Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345–53. https://doi.org/10.1007/s00330-016-4308-4.

    Article  PubMed  Google Scholar 

  22. Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, et al. [(18)F]Fluoroethyl triazole substituted PSMA inhibitor exhibiting rapid normal organ clearance. Bioconjug Chem. 2016;27:1655–62. https://doi.org/10.1021/acs.bioconjchem.6b00195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

We acknowledge funding for this study from FutureChem Co, Ltd.

Author information

Authors and Affiliations

  1. The Russell H. Morgan, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St. JHOC Room 3233, Baltimore, MD, 21287, USA

    Sara Sheikhbahaei, Ricardo Bello Martinez, Mary Katherine Brosnan, Ergi Spiro, Rehab AbdAllah, Daniel P. Holt, Robert F. Dannals, Rudolf A. Werner, Martin G. Pomper, Lilja B. Solnes & Steven P. Rowe

  2. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Mark C. Markowski, Mario A. Eisenberger, Martin G. Pomper, Lilja B. Solnes & Steven P. Rowe

  3. The Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Kenneth J. Pienta, Diane Reyes, Martin G. Pomper & Steven P. Rowe

  4. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

    Rudolf A. Werner

  5. Milton and Carroll Petrie, Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Michael A. Gorin

Authors
  1. Sara Sheikhbahaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricardo Bello Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark C. Markowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mario A. Eisenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenneth J. Pienta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diane Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mary Katherine Brosnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ergi Spiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rehab AbdAllah
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel P. Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Robert F. Dannals
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rudolf A. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Martin G. Pomper
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Michael A. Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lilja B. Solnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Steven P. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Sheikhbahaei.

Ethics declarations

Conflict of interest

MGP has equity in FutureChem USA, a subsidiary of FutureChem Co, Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheikhbahaei, S., Bello Martinez, R., Markowski, M.C. et al. Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging. Ann Nucl Med 37, 246–254 (2023). https://doi.org/10.1007/s12149-023-01823-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-023-01823-2

Keywords

Search

Navigation